Log in to search using one of your social media accounts:

This page shows you the latest news items in this category.

XELJANZ ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). (Source: World Pharma News)
Source: World Pharma News - March 27, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Mobile gold fingers
(Wiley) Drugs containing gold have been used for centuries to treat conditions like rheumatoid arthritis. In addition, they might be effective against cancer and HIV. One mechanism by which they work could occur because gold ions force the zinc ions out of zinc fingers -- looped, nucleic acid binding protein domains. American researchers have characterized such 'gold fingers' using ion mobility mass spectrometry. As reported in the journal Angewandte Chemie, they identified the exact gold binding sites. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 27, 2017 Category: Global & Universal Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hi...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New tool to treat rheumatoid arthritis discovered
A Swedish study suggests antibodies against the cartilage protein collagen II could aid in predicting prognosis and therapy choice for rheumatoid arthritis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 23, 2017 Category: Consumer Health News Source Type: news

New tool for prognosis and choice of therapy for rheumatoid arthritis
(Uppsala University) In rheumatoid arthritis, antibodies are formed that affect the inflammation in the joints. In an article published today in the journal Annals of the Rheumatic Diseases, researchers at Uppsala University show that antibodies against the cartilage protein collagen II are associated with a good prognosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2017 Category: Global & Universal Source Type: news

New biomarker 'could aid prediction of rheumatoid arthritis outcomes'
A new biomarker has been discovered that could make it easier to predict which rheumatoidarthritis patients are most likely to experience a positive prognosis. Researchers at Uppsala University have carried out a study showing that antibodies against the cartilage protein collagen II are associated with better outcomes, and could be helpful in determining the best treatment to use for each patient. A link between collagen antibodies and disease development For this study, a large group ofrheumatoid arthritis patients were followed over five years to establish a possible correlation between collagen antibody levels and dise...
Source: Arthritis Research UK - March 23, 2017 Category: Rheumatology Source Type: news

New Enterprise Associates gets in on SetPoint Medical
SetPoint Medical said today that it has received an investment from venture capital firm New Enterprise Associates. SetPoint is developing a neuromodulation device designed to stimulate the vagus nerve to trigger the body’s anti-inflammatory response, according to the company. Newly vested NEA joins existing investors Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX), GlaxoSmithKline‘s (NYSE:GSK) Action Potential Venture Capital Limited, Morgenthaler Ventures and Topspin Partners. “We are proud that SetPoint has attracted such a prestigious and experienced investor. NEA is known for its support of companies...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Neuromodulation/Neurostimulation SetPoint Medical Source Type: news

UCB works with Garmin on wellness program for rheumatoid arthritis patients
Global pharmaceutical company UCB has launched Wellness4U, a health and wellness platform for  people living with immunologic disorders which includes, as one aspect, an activity tracker pilot program. (Source: mobihealthnews)
Source: mobihealthnews - March 20, 2017 Category: Information Technology Source Type: news

Biologic-Naive PsA Patients Persist on Therapy (CME/CE)
(MedPage Today) -- Pattern similar to what is seen in rheumatoid arthritis (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 19, 2017 Category: Dermatology Source Type: news

Oxford BioDynamics joins collaboration to identify biological factors that cause RA flares
UK-based biotechnology company Oxford BioDynamics has participated in a collaboration to identify biological factors that cause disease relapses, known as flares, in patients with rheumatoid arthritis (RA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 17, 2017 Category: Pharmaceuticals Source Type: news

Modified red blood cells 'could alleviate autoimmune diseases'
This study is interesting and has the potential to be a tool used to both treat and prevent rheumatoid arthritis. It is promising to see that autoimmunity could be treated in mice, but people with arthritis need to be aware that this research is in its very early stages. "More research is needed to determine how the results can be translated into a benefit for people living inpain now, and for those who may develop arthritis in the future." (Source: Arthritis Research UK)
Source: Arthritis Research UK - March 17, 2017 Category: Rheumatology Source Type: news

What Chrissy Teigen Can Teach Us About Postpartum Depression
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.    If you or someone you know needs help, call 1-800-273-8255 for the National Suicide Prevention Lifeline. You can also text HELLO to 741-741 for free, 24-hour support from the Crisis Text Line. Outside of the U.S., please visit the International Association for Suicide Prevention for a database of resources. -- This feed and its contents are the property of The Huffington Post, and use is subject to our t...
Source: Healthy Living - The Huffington Post - March 15, 2017 Category: Consumer Health News Source Type: news

Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All
Title: Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After AllCategory: Health NewsCreated: 3/6/2017 12:00:00 AMLast Editorial Review: 3/7/2017 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - March 7, 2017 Category: Anesthesiology Source Type: news

No Benefit of Rheumatoid Arthritis Drug in Chronic Fatigue Syndrome (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The interleukin-1 receptor antagonist anakinra doesn ' t seem to reduce fatigue in women with chronic fatigue syndrome, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 6, 2017 Category: Primary Care Source Type: news

Your NEJM Group Today: Histology Rings True / Probiotics for C. diff / Illinois IM Opportunity (FREE)
By the Editors Here ' s today ' s offering from NEJM Group:NEJM Clinical Practice Center: Clinical Problem-Solving: A 58-year-old man with nonerosive rheumatoid arthritis who was being treated with etanercept … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 6, 2017 Category: Primary Care Source Type: news

Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All
With disappointing study results, there's still no cure for the mysterious disorderSource: HealthDay Related MedlinePlus Pages: Chronic Fatigue Syndrome, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 6, 2017 Category: Consumer Health News Source Type: news

Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All
MONDAY, March 6, 2017 -- A small-scale clinical trial has cast doubt upon the potential usefulness of an anti-inflammatory drug to treat chronic fatigue syndrome. Doctors had hoped that anakinra (Kineret) -- a medication for rheumatoid arthritis --... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 6, 2017 Category: Journals (General) Source Type: news

Autoimmune Diseases Linked to Dementia Autoimmune Diseases Linked to Dementia
A new study linking autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, and later dementia strengthens the hypothesis that Alzheimer ' s may have an autoimmune component, researchers say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 3, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Scientists discover new mechanism that leads to inflammation in rheumatoid arthritis
New research findings suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 2, 2017 Category: Science Source Type: news

Scientists discover metabolic pathway that drives tumor growth in aggressive cancers
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have discovered that a rheumatoid arthritis drug can block a metabolic pathway that occurs in tumors with a common cancer-causing gene mutation, offering a new possible therapy for aggressive cancers with few therapeutic options, according to a study to be published in Cancer Discovery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 2, 2017 Category: Biology Source Type: news

Scientists discover new mechanism that leads to inflammation in rheumatoid arthritis
(Federation of American Societies for Experimental Biology) New research findings published in the Journal of Leukocyte Biology (http://www.jleukbio.org), suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 2, 2017 Category: Global & Universal Source Type: news

Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Comprehensive patient support program also announced MISSISSAUGA, ON, Feb. 28, 2017 (Healthcare Sales & Marketing Network) - Sanofi Genzyme, the specialty business unit of sanofi-aventis Canada Inc., is pleased to announced the Canadian availability of... Biopharmaceuticals, Product Launch Sanofi, Sanofi Genzyme, Regeneron Pharmaceuticals, Kevzara, sarilumab, arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 28, 2017 Category: Pharmaceuticals Source Type: news

Men 'face unique challenges when coping with rheumatoid arthritis'
Men with rheumatoidarthritis are often struggling to cope with their condition due to unique challenges created by their identities and self-perception, according to a new study. Research carried out by the University of West England and funded by Arthritis Research UK has indicated that men face specific problems when dealing mentally withrheumatoid arthritis that women do not share - and that tailored channels of support may be needed to help them cope. The unique struggles faced by men The study centred on a series of interviews carried out among six focus groups comprising 22 men, who were asked about their experiences...
Source: Arthritis Research UK - February 28, 2017 Category: Rheumatology Source Type: news

Binding immunoglobulin protein therapy shows promise for rheumatoid arthritis
A promising new approach to treating rheumatoidarthritis using binding immunoglobulin protein (BiP) therapy has shown its potential in a new clinical study. Carried out by King's College London and Guys and St Thomas' NHS Foundation Trust Hospital, the research has indicated that BiP-based treatment could represent a useful intervention for patients who have failed to respond to conventional disease-modifying antirheumaticdrugs (DMARDs). How it works BiP belongs to a class of compounds known as human endoplasmic reticulum-resident stress proteins, and has been shown in preclinical studies to offer anti-inflammatory...
Source: Arthritis Research UK - February 27, 2017 Category: Rheumatology Source Type: news

Masonic Charitable Foundation awards grant to microbiome research
The Masonic Charitable Foundation has awarded£90,000 over three years to Arthritis Research UK, to support research into the role of the microbiome in rheumatoid arthritis.The grant will support Dr Frances Williams at King’s College London, to explore whether the mix of bacteria in and on our bodies (known as the microbiome) drives rheumatoid arthritis, or whether changes in these bacteria are a consequence of the disease or the drugs used to treat it.The researchAround 400,000 people in the UK have rheumatoid arthritis but the best drugs available do not work for everyone. We know that the microbiome in people...
Source: Arthritis Research UK - February 27, 2017 Category: Rheumatology Source Type: news

Clues to relationship between schizophrenia and rheumatoid arthritis
A bioinformatics study identifies genetic variants with differing effects on risk of rheumatoid arthritis and schizophrenia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 24, 2017 Category: Science Source Type: news

Pitt study provides clues to relationship between Schizophrenia and Rheumatoid arthritis
(University of Pittsburgh Schools of the Health Sciences) Bioinformatics study identifies genetic variants with differing effects on risk of rheumatoid arthritis and schizophrenia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 24, 2017 Category: Global & Universal Source Type: news

New assay may lead to a cure for debilitating inflammatory joint disease
Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses. Known as autoantibodies and produced by the immune system ' s B cells, these defective molecules mistakenly attack the body ' s own proteins in an example of autoimmune disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 24, 2017 Category: Science Source Type: news

New assay may lead to a cure for debilitating inflammatory joint disease
(NYU Langone Medical Center / New York University School of Medicine) Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses. Known as autoantibodies and produced by the immune system's B cells, these defective molecules mistakenly attack the body's own proteins in an example of autoimmune disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2017 Category: Global & Universal Source Type: news

Baricitinib Might Offer Oral Alternative to Adalimumab in RA Baricitinib Might Offer Oral Alternative to Adalimumab in RA
A phase 3 trial in patients with rheumatoid arthritis who did not respond to methotrexate showed that the addition of baricitinib produced significant clinical improvements.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Drug used to treat arthritis could save stroke patients
British doctors are trialling the use of a rheumatoid arthritis drug which targets the inflammatory process in the brain caused by stroke in the same way it treats inflammation in an arthritic joint. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2017 Category: Consumer Health News Source Type: news

Diabetes or rheumatoid arthritis - conditions put YOU at greater risk of THIS disease
DIABETES is not the only condition which can increase the risk of developing heart disease. Rheumatoid arthritis sufferers are also at greater risk of of developing the potentially deadly condition. (Source: Daily Express - Health)
Source: Daily Express - Health - February 17, 2017 Category: Consumer Health News Source Type: news

Rheumatoid Arthritis Guidance for Patients, by Patients Rheumatoid Arthritis Guidance for Patients, by Patients
Medscape speaks with Dr Jonathan Krant about a new resource for patients with rheumatoid arthritis, which was developed in part by patients.Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 17, 2017 Category: Consumer Health News Tags: Rheumatology Expert Interview Source Type: news

MI Risk 39% Lower for Patients With RA Taking TNF Inhibitors MI Risk 39% Lower for Patients With RA Taking TNF Inhibitors
Patients with rheumatoid arthritis who were treated with TNF inhibitors were less likely to develop myocardial infarction than those treated with conventional DMARDs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 16, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Eli Lilly and Incyte receive EC ’s marketing authorisation approval for Olumiant
Eli Lilly and Incyte have secured marketing authorisation approval for Olumiant (baricitinib) 4mg and 2mg film-coated tablets from the European Commission (EC) to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 15, 2017 Category: Pharmaceuticals Source Type: news

Self-reported childhood maltreatment and traumatic events among Israeli patients suffering from fibromyalgia and rheumatoid arthritis - Hellou R, H äuser W, Brenner I, Buskila D, Jacob G, Elkayam O, Aloush V, Ablin JN.
OBJECTIVE. The association between Fibromyalgia Syndrome (FMS) and childhood maltreatment and adversity has frequently been proposed but limited data exists regarding the transcultural nature of this association. METHODS. 75 Israeli FMS patients an... (Source: SafetyLit)
Source: SafetyLit - February 14, 2017 Category: Global & Universal Tags: Age: Adolescents Source Type: news

European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the Eur... Biopharmaceuticals, Regulatory Eli Lilly, Incyte , Olumiant, baricitinib, rheumatoid arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2017 Category: Pharmaceuticals Source Type: news

Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases
Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site. (Source: World Pharma News)
Source: World Pharma News - February 10, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Rheumatoid Arthritis: Living With a Chronic Disease
Title: Rheumatoid Arthritis: Living With a Chronic DiseaseCategory: Doctor's& Expert's views on SymptomsCreated: 1/19/2012 12:00:00 AMLast Editorial Review: 2/9/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 9, 2017 Category: Rheumatology Source Type: news

Patient Story: Rheumatoid Arthritis Treatment
Title: Patient Story: Rheumatoid Arthritis TreatmentCategory: Doctor's& Expert's views on SymptomsCreated: 1/20/2012 12:00:00 AMLast Editorial Review: 2/9/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 9, 2017 Category: Rheumatology Source Type: news

Study of complex genetic region finds hidden role of NCF1 in multiple autoimmune diseases
(Medical University of South Carolina) Medical University of South Carolina investigators report pre-clinical research showing that a genetic variant encoded in neutrophil cystolic factor 1 (NCF1) is associated with increased risk for autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sj ö gren's syndrome, in the January 2017 issue of Nature Genetics. Data indicate that increased NCF1 protects against SLE while decreased NCF1 raises SLE risk and highlight the pathogenic role of reduced reactive oxygen species in autoimmune disease development. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 8, 2017 Category: Biology Source Type: news

Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?
Title: Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?Category: MedicineNet QuizCreated: 1/31/2011 12:00:00 AMLast Editorial Review: 2/6/2017 12:23:33 PM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 6, 2017 Category: Rheumatology Source Type: news

Medical News Today: Seronegative Rheumatoid Arthritis: Symptoms, Diagnosis, and Treatment
What is seronegative rheumatoid arthritis? What is rheumatoid factor? Learn about what tests may be used and if diet can help to manage symptoms. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 3, 2017 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Health Canada approves Kevzara antibody to treat patients with rheumatoid arthritis
Sanofi has received approval from Health Canada for Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, to treat adult patients with moderately to severely active rheumatoid arthritis (RA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 2, 2017 Category: Pharmaceuticals Source Type: news

Drug combination effective against chikungunya arthritis in mice
Chikungunya virus causes a painful, debilitating arthritis for which there is currently no treatment. A new study has found that combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the earliest stage of the disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 1, 2017 Category: Science Source Type: news

Discovery of new T-cell subtype opens window on rheumatoid arthritis
Researchers have carefully scrutinized the immune cells from patients with rheumatoid arthritis, revealing a striking new subset of T-cells that collaborate with other immune cells to drive inflammation in peripheral tissues. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 1, 2017 Category: Science Source Type: news

Use of Biologic Therapy in Racial Minorities With RA Use of Biologic Therapy in Racial Minorities With RA
A new study investigates possible racial and ethnic disparities in the access and administration of biologic agents for rheumatoid arthritis. Are there discrepancies?Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Drug combination effective against chikungunya arthritis in mice
(Washington University School of Medicine) Chikungunya virus causes a painful, debilitating arthritis for which there is currently no treatment. A new study has found that combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the earliest stage of the disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 1, 2017 Category: Infectious Diseases Source Type: news

Discovery of New T-Cell Subtype Opens Window on Rheumatoid Arthritis
Finding flows from researchers ’ use of high-tech tools to deeply and efficiently characterize patient cells (Source: BWH News)
Source: BWH News - February 1, 2017 Category: Hospital Management Source Type: news